2023 Pediatric Rheumatology Symposium

March 29-April 1, 2023. New Orleans, LA.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a b c [d] e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 096

DADA2 – a Case Series from North India
Abstract Number: 087

Delays in Care, Declines in Health, and Food Insecurity in Pediatric Systemic Lupus Erythematosus Patients During the COVID-19 Pandemic
Abstract Number: 019

Developing Standard Improvement Curves for Disease Activity, Pain and Quality of Life in Children with Newly Diagnosed Juvenile Idiopathic Arthritis: Results from the CAPRI Registry
Abstract Number: 043

Development and Usability Testing of Web-based Standardized Scoring Tool for Magnetic Resonance Images from Children with Chronic Nonbacterial Osteomyelitis (CNO)
Abstract Number: 115

Development of an Electronic Clinical Phenotype to Identify Potential Study Subjects with Juvenile Arthritis
Abstract Number: 108

Development of Mental Health Guidance Statements for Pediatric Rheumatology
Abstract Number: 123

Development of Specific Classification Criteria for Juvenile System Sclerosis Patients: A Scoping Review
Abstract Number: 101

Differences in Clinical and Patient-reported Outcomes in Juvenile Dermatomyositis by Race and Ethnicity
Abstract Number: 021

Distinguishing Childhood Sjogren’s Disease in Patients Presenting with Recurrent Sialadenitis in a Multidisciplinary Clinic
Abstract Number: 079

Dynamics of Neutrophil Activation in Repeated TLR-9-Induced Mouse Model of Macrophage Activation Syndrome

Jump to: View All • a b c [d] e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].